Peptides are amino acids’ short chains connected through peptide bonds. Peptides are molecules that are commonly known as proteins, whose functions are determined on the basis of the amino acid sequence and size.
Heparin is known as disaccharide anticoagulant, commonly referred to as blood thinner, which prevents formation of blood clots. Mast cells and basophils in a body produce heparin, which is stored in mast cells and secreted wherever injuries occur.
Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules
While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products.
However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains.
Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses.
For example, original requirement for injecting peptides such as insulin is fading, with more patient-friendly administrations progressively being developed.
In addition, the current society that critically judges undesirable effects and environmental impact of the candidate medicines is embracing the safety offered by peptides.
Heparin is being extensively employed as an antitumor and anti-inflammatory agent. The anti-inflammatory characteristic of heparin, which prevents metastatic spreading of tumor cells, is a new research finding among healthcare professionals.
The metastatic spreading of tumor cells is restricted by heparin through neutralization of cationic mediators, inhibition of heparanase, and adhesion molecules.
Recent discoveries have meant that heparin is capable of targeting L- and P-selectin & integrin activity, as well as preventing cancer progression.
A new report by Fact.MR projects the global peptide and heparin market to reflect an impressive expansion during the forecast period, 2017 to 2026. Revenues from the market are estimated to exceed US$ 34,000 Mn by 2026-end.
Know More Details About the Report
APEJ to Remain Most Remunerative Market for Peptide and Heparin
There has been a growing demand for new oral anticoagulants having better efficacy and safety profiles in Asia-Pacific excluding Japan (APEJ).
Side effects related to heparin products, including complications of bleeding and heparin-induced thrombocytopenia has resulted into robust adoption of oral anticoagulants in the region.
In addition, rising incidence of cancer, metabolic disorders, and hepatitis, along with advancements in peptide synthesis technology and rapid demand for various peptide therapies in the region are expected to drive the growth in APEJ. APEJ will remain the most remunerative market for peptide and heparin.
Liraglutide and ammonium heparin are expected to remain fast-expanding products in the market. In addition, sales of exenatide, lithium heparin, and sodium heparin will register a similar CAGR through 2026.
Key Research Findings from Fact.MR’s Report on Peptide and Heparin Market
- Oral route of administration will remain preferred for peptide and heparin
- Cancer will continue to be the dominant indication segment in the market, in terms of revenues
- Hospital pharmacies will remain the most lucrative distribution channel for peptide and heparin
Avail customized purchase options for your needs
The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors.
These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas.
Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future.
Key market participants identified by the report include
- Biofer S.p.A,
- Hemmo Pharma
- AmbioPharm Inc.
- Wockhardt Ltd.
- Sun Pharmaceutical Industries Ltd.
- Abbott Laboratories
- Pfizer Inc
- Leo Pharma
- Novo Nordisk
- Eli Lilly.
|Route of Administration||
Peptides and Heparin Market Scope Of The Report
Growth of the global peptide and heparin market is expected to remain affected by key factors such as rising prevalence of chronic ailments, alleviated demand for effective drugs & technology, new product developments, and rising investments by leading market players in R&D activities.
This Fact.MR report analyzes the expansion of global peptide and heparin market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.
The scope of Fact.MR’s report is to analyze the global peptide and heparin market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis.
Medical device manufacturers, research institutes, and raw material suppliers in the global peptide and heparin market can benefit from the analysis offered in this report.
This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide and heparin.
The report commences with a brief information of the global peptide and heparin market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide and heparin market.
The next section offers an overview of the global peptide and heparin market. This comprises an introduction to the market, along with a standard definition of the product – peptide and heparin.
In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.
The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.
In order to offer readers with up-to-date information about the latest advancements in the global peptide and heparin market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide and heparin.
With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide and heparin manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.
The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide and heparin market.
Key segments that define growth of the global peptide and heparin market include product type, route of administration, indication, distribution channel, and region. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.
The report’s last section comprises of the global peptide and heparin market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide and heparin market.
Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research.
We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.